Optometry Times Staff Reports

The trial will enroll approximately 111 patients across the US and Europe following positive FDA feedback from a Type D meeting

Through at home delivery, and in-office dispense in permitted states, Orasis Pharmaceuticals and BlinkRx aim to improve accessibility of Qlosi eye drops for presbyopia treatment.

The FDA confirmed phase 1 and nonclinical data support pediatric phase 2 development of IVMED-85, a non-atropine daily eye drop for myopia progression.

Bausch + Lomb’s EyeGility preloaded enVista IOL inserter streamlines cataract surgery with push-plunger delivery, less handling, and faster workflow.

Frantz EyeCare reported 98% of Light Adjustable Lens patients within ±0.50 D of target but omitted cohort, follow-up, and safety details.

i-Lumen Scientific randomly assigned its first US patient in the sham-controlled i-SIGHT2 pivotal study of its investigational, noninvasive bioelectric AMD device at Texas Retina Associates.

A 10-year analysis finds latanoprost accounts for 40% of glaucoma prescriptions in New Zealand.

Lab-grown retinal endothelial cells from iPSCs rebuild mouse retinal vessels and power blood-retina barrier chips, accelerating diabetic retinopathy research and therapy discovery.

University of Waterloo unveils chairside 3D-printed contacts, delivering custom-fit lenses in 20 minutes—potentially cutting weeks of trial fittings for irregular corneas.

NEI-funded US trial compares HALT MAX lenses, 0.05% atropine, and combination therapy to slow childhood myopia and axial elongation.

The non-exclusive license agreement pairs Alcon's PCIOL optical designs with RxSight's post-operative light-adjustable platform, with the aim of allowing surgeons to fine-tune visual outcomes after cataract surgery.

A new pilot trial tests ZOC2017217 lanosterol-derived cataract eye drops, aiming to slow lens clouding and guide Phase 3 development amid mixed human evidence.

Antineoplastics were the most frequently implicated drug class in review

The company said it will now focus solely on developing what it describes as the first small-molecule sustained-release implant for geographic atrophy, with clinical trials expected to begin in 2028.

Alcon's TikTok, YouTube, and Instagram campaign uses creator-led patient stories to reintroduce LASIK to younger consumers and prompt conversations with surgeons.

Healome’s proprietary eye drop-matrix behaves like a liquid when it is dropped on the eye, and then restructures on the ocular surface to form a clear, lubricating, protective matrix that can deliver a broad range of drugs.

Yuvezzi (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% is a once-daily, dual-agent eye drop, for the treatment of presbyopia in adults.

The approval is backed by Phase 3 bridging data—expanding EyeSol options and intensifying market rollout.

LENZ Therapeutics and Arrotex Pharmaceuticals announce exclusive license and commercialization agreement for Vizz in Australia and New Zealand.

The relationship between ALAN exposure and myopia was found to be non-linear.

In a preference study, Karl Csaky, MD, PhD and colleagues found that lesion growth rate reduction was the primary driver of GA treatment decisions among US retina specialists, with greater risk tolerance for foveal-threatening lesions.

A large real-world cohort study by Takashi Nishida, MD, PhD et al finds OSA is associated with elevated glaucoma risk.

According to the survey, one in five sufferers reported that dry eye symptoms affect their self-confidence (22%) and emotional wellbeing (20%).

FDA clears Lumvoa for active and chronic thyroid eye disease, offering rapid proptosis and diplopia gains—plus key safety monitoring tips.

ZEISS partners with Envision to expand evidence-backed VR perimetry, enabling more accessible, gamified home visual field testing for glaucoma monitoring.

A cross-sectional study of nearly 10,000 nursing home residents found a clear dose-response relationship between vision loss and cognitive impairment, with blind residents having nearly 3 times the odds of cognitive loss compared with those with normal vision.

A Johnson & Johnson Vision poster found a novel multifocal toric daily disposable contact lens delivered visual acuity within 1 letter and comparable fitting success to an existing nontoric multifocal lens, extending coverage to presbyopes with up to 1.75D astigmatism.

A systematic review of 22 studies found Demodex infestation strongly associated with MGD, with MGD prevalence reaching 92% to 99% in symptomatic Demodex blepharitis and significantly worse meibomian gland structure and function in infested patients.

A real-world pilot across 8 optometric sites found Qlosi (0.4% pilocarpine) implementation met or exceeded all corporate KPIs, with UWF imaging utilization rising 16.4 percentage points and 72.7% of patients achieving personal treatment goals.

GATHER2 OLE data through 3.5 years show avacincaptad pegol reduced GA lesion growth by 28.8% in continuously treated patients and 37% to 40% in those switched from sham, with no new safety signals.